Randomized trial of bevacizumab in advanced renal cell carcinoma

被引：0
|
作者：
Ronald M. Bukowski
机构：
来源：
Current Oncology Reports | 2008年 / 10卷
关键词：
Renal Cell Carcinoma; Bevacizumab; Clin Oncol; Sorafenib; Erlotinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：99 / 100
页数：1
相关论文
共 50 条
  • [1] Randomized Trial of Bevacizumab in Advanced Renal Cell Carcinoma
    Bukowski, Ronald M.
    CURRENT ONCOLOGY REPORTS, 2008, 10 (02) : 99 - 100
  • [2] Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
    Hainsworth, John D.
    Spigel, David R.
    Burris, Howard A., III
    Waterhouse, David
    Clark, Bobby L.
    Whorf, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2131 - 2136
  • [3] The bevacizumab experience in advanced renal cell carcinoma
    Harshman, Lauren C.
    Srinivas, Sandy
    ONCOTARGETS AND THERAPY, 2010, 3 : 179 - 189
  • [4] Randomized Phase III Trial of Temsirolimus and Bevacizumab Versus Interferon Alfa and Bevacizumab in Metastatic Renal Cell Carcinoma: INTORACT Trial
    Rini, Brian I.
    Bellmunt, Joaquim
    Clancy, Jill
    Wang, Kongming
    Niethammer, Andreas G.
    Hariharan, Subramanian
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (08) : 752 - +
  • [5] Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
    Bazarbashi, Shouki
    Alzahrani, Ahmed
    Aljubran, Ali
    Elshenawy, Mahmoud
    Gad, Ahmed Mostafa
    Maraiki, Fatima
    Alzannan, Noura
    Elhassan, Tusneem
    Badran, Ahmed
    ONCOLOGIST, 2023, 28 (05): : E254 - E262
  • [6] Bevacizumab as a treatment option in advanced renal cell carcinoma: An analysis and interpretation of clinical trial data
    McDermott, David F.
    George, Daniel J.
    CANCER TREATMENT REVIEWS, 2010, 36 (03) : 216 - 223
  • [7] A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma
    Voss, M. H.
    Hussain, A.
    Vogelzang, N.
    Lee, J. L.
    Keam, B.
    Rha, S. Y.
    Vaishampayan, U.
    Harris, W. B.
    Richey, S.
    Randall, J. M.
    Shaffer, D.
    Cohn, A.
    Crowell, T.
    Li, J.
    Senderowicz, A.
    Stone, E.
    Figlin, R.
    Motzer, R. J.
    Haas, N. B.
    Hutson, T.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2754 - 2760
  • [8] Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
    Negrier, Sylvie
    Gravis, Gwenaelle
    Perol, David
    Chevreau, Christine
    Delva, Remy
    Bay, Jacques-Olivier
    Blanc, Ellen
    Ferlay, Celine
    Geoffrois, Lionnel
    Rolland, Frederic
    Legouffe, Eric
    Sevin, Emmanuel
    Laguerre, Brigitte
    Escudier, Bernard
    LANCET ONCOLOGY, 2011, 12 (07): : 673 - 680
  • [9] Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: A phase I/II trial
    Hainsworth, John D.
    Spigel, David R.
    Sosman, Jeffrey A.
    Burris, Howard A., III
    Farley, Cindy
    Cucullu, Heather
    Yost, Kathleen
    Hart, Lowell L.
    Sylvester, Linda
    Waterhouse, David M.
    Greco, F. Anthony
    CLINICAL GENITOURINARY CANCER, 2007, 5 (07) : 427 - 432
  • [10] Reappraisal of the Role of Bevacizumab in the Therapeutic Strategy in Advanced Renal Cell Carcinoma
    Guillot, Aline
    Levy, Antonin
    Pacaut, Cecile
    Collard, Olivier
    Massard, Christophe
    Merrouche, Yacine
    Magne, Nicolas
    CLINICAL GENITOURINARY CANCER, 2012, 10 (03) : 147 - 152
12345